Neoantigen Targeted Therapies Global Market Report 2024 - By Share, Size, Key Trends, Demand And Analysis, Forecast To 2033

"The new report published by The Business Research Company, titled Neoantigen Targeted Therapies Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the neoantigen targeted therapies market size has grown exponentially in recent years. It will grow from $2.43 billion in 2023 to $3.39 billion in 2024 at a compound annual growth rate (CAGR) of 39.3%. The neoantigen targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $11.69 billion in 2028 at a compound annual growth rate (CAGR) of 36.3%.

Download Free Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=11944&type=smp

Rising Incidence Of Cancer Cases Drives Growth In The Neoantigen Targeted Therapies Market
The increasing incidence of cancer cases is expected to propel the growth of the neoantigen targeted therapies market going forward. The incidence of cancer refers to the number of new cases of cancer in a specific population for a given period. Neoantigen targeted therapies are often used in combination to treat different types of cancer. For instance, the American Cancer Society (ACS), a US-based voluntary health organization, in 2022, the United States had 1.9 million new cancer cases, representing a significant increase compared to previous years. Furthermore, in 2022, in the US, approximately 609,360 deaths were attributed to cancer, emphasizing the profound severity and impact of this disease on individuals and their families. Therefore, the increasing incidence of cancer cases is driving the growth of the neoantigen targeted therapies market.

Biontech Takes Strides In Neoantigen Targeted Therapies With The Launch Of Bnt122 For Colorectal Cancer
Product innovation has emerged as a key trend gaining popularity in the neoantigen targeted therapies market. Major players are focusing on creating innovative products to lead the market. For instance, in October 2021, BioNTech, a Germany-based biotechnology company, expanded its clinical oncology portfolio with the initiation of a Phase 2 clinical trial for 'BNT122', a mRNA-based individualized immunotherapy. This trial specifically focuses on colorectal cancer patients. The trial marks an important milestone, as the first patient has been dosed with BNT122. It is designed to harness the power of the immune system by stimulating a targeted T-cell response against neoantigens found in each patient's tumor. The ongoing clinical trial represents an important step forward in BioNTech's mission to develop cutting-edge immunotherapies and expand the treatment options available to cancer patients.

The neoantigen targeted therapies market covered in this report is segmented -
1) By Type: Monotherapy, Combination Therapy
2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies
3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer
4) By Route of Administration: Intradermal, Intravenous, Subcutaneous
5) By Application: Medical Research Institution, Hospital, and Clinic, Other Applications

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=11944&type=discount

Major companies operating in the neoantigen targeted therapies market report are F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Kite Pharma Inc., Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Precision Biologics Inc., Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

Contents of the report:
1. Executive Summary
2. Neoantigen Targeted Therapies Market Report Structure
3. Neoantigen Targeted Therapies Market Trends And Strategies
4. Neoantigen Targeted Therapies Market - Macro Economic Scenario
5. Neoantigen Targeted Therapies Market Size And Growth
…..
27. Neoantigen Targeted Therapies Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @
https://www.thebusinessresearchcompany.com/report/neoantigen-targeted-therapies-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ"

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.